Greater Asia News
Astellas to Acquire Propella Therapeutics
Astellas, through a U.S. subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella.
Flagship expands into Asia-Pacific with new Singapore hub
Biotechnology company creator Flagship Pioneering is expanding its global footprint, announcing Tuesday the establishment of a regional hub in Singapore.
Japan to scrap rule requiring testing of new drugs on Japanese
apan will ease regulations on clinical trials for new drugs developed overseas, Nikkei has learned, scrapping the rule that in principle drugs' safety must be tested on Japanese before they can be launched in the domestic market.
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
The approval of FRUZAQLA is based on data from two large Phase 3 trials: the multi-regional FRESCO-2 trial, data from which were published in The Lancet, along with the FRESCO trial conducted in China, data from which were published in JAMA.
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
The U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
Under this transaction, Bristol Myers Squibb has acquired Orum’s ORM-6151 program for an upfront payment of $100 million, and Orum Therapeutics is eligible to receive milestone payments for a total deal value of $180 million. Further details were not disclosed.
Chong Kun Dang partners with Novartis in historic $1.3 billion deal
Pharmaceutical company Chong Kun Dang signed a $1.3-billion technology transfer agreement with Novartis for its rare genetic disease treatment candidate.
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
This milestone marks the first market approval for a drug originating from Genexine's research and development with KGbio.
Novartis claims ex-staffer jumped to Takeda with ‘thousands’ of sensitive files
Novartis believes a former employee of its Egyptian affiliate made off with thousands of files before jumping ship to Takeda.
Kyowa Kirin to Acquire Orchard Therapeutics
Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, today announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics
